Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course. Whether to continue or to stop TMZ is a complex and stressful decision for the patient and family, and the decision should be based on a discussion of the known risks and benefits of each choice.
Austin Brain Tumor Center, Texas Oncology, Texas, USA. morris.groves@usoncology.com
Morris D
MD
Groves
Ava B
AB
Plummer
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000523:psychology; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008875:Middle Aged; D019635:Neurosurgical Procedures; D010817:Physician-Patient Relations; D010818:Practice Patterns, Physicians'; D011878:Radiotherapy; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide